SUMO1 Enhances cAMP-Dependent Exocytosis and Glucagon Secretion from Pancreatic α-Cells
Scientists sought to determine whether small ubiquitin‐like modifier‐1 (SUMO1) modulates mouse and human α-cell function. Action potentials, ion channel function, and exocytosis in single α-cells from mice and humans, identified by glucagon immunostaining, and glucagon secretion from intact islets were measured. [J Physiol]
Abstract
Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
INDUSTRY NEWS
Collaboration of Research Organizations Aims to Advance Field of Pancreatic Cancer
The Pancreatic Cancer Action Network, Rising Tide Foundation for Clinical Cancer Research and Gateway for Cancer Research have joined forces to fight one of the deadliest and hardest-to-treat cancers. The strategic collaboration has provided $1 million to facilitate and accelerate pancreatic cancer clinical research, with the Pancreatic Cancer Action Network supporting an additional translational project for $250,000. [Pancreatic Cancer Action Network]
Press Release
Halozyme to Resume PEGPH20 Clinical Program in Pancreatic Cancer
Halozyme Therapeutics, Inc. announced that the U.S. Food and Drug Administration has removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase II trial evaluating PEGPH20 in patients with pancreatic cancer permitting the study to resume under a revised protocol. [Halozyme Therapeutics, Inc.]
Press Release
Recruit Top Talent: Reach more than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!
Comments or Suggestions? Submit your feedback here.